FDA Reverses Course to Clear Path for Landmark Huntington's Gene Therapy

The FDA has reversed its stance on a groundbreaking gene therapy for Huntington's disease, clearing the way for what could become the first disease-modifying treatment for the fatal genetic disorder. On June 17, 2026, the agency informed Dutch biotech UniQure that existing three-year clinical data is sufficient to file for accelerated approval of its drug, AMT-130.[1]

The decision marks the end of a volatile regulatory odyssey and a major victory for patient advocates. Huntington's disease, which affects an estimated 30,000 to 41,000 Americans, causes the progressive breakdown of nerve cells in the brain, leading to severe motor, cognitive, and psychiatric decline. Currently, there are no approved treatments that alter the course of the disease.[1]

AMT-130 represents a highly targeted approach to the condition. The therapy uses an adeno-associated virus (AAV5) vector to deliver an artificial micro-RNA directly into the brain. This micro-RNA is designed to silence the mutated huntingtin gene, inhibiting the production of the toxic protein that destroys neurons. Because it is a one-time treatment, it requires a stereotactic neurosurgical procedure to deliver the vector directly into the striatum.[2][3]

The core of the evidence pack supporting AMT-130 comes from a Phase 1/2 clinical trial involving 29 patients. Because Huntington's is a rare and uniformly fatal disease, UniQure compared the outcomes of treated patients against a "natural history" control group—a matched cohort of untreated patients from observational databases.[1][2]

The strongest clinical evidence for the therapy emerged in September 2025, when 36-month data showed that patients receiving a high dose of AMT-130 experienced a 75% slowing of disease progression. This was measured using the Composite Unified Huntington's Disease Rating Scale (cUHDRS), a rigorous metric combining motor, cognitive, and functional assessments.[2][3]

Furthermore, the trial met a key secondary endpoint, demonstrating a 60% slowing in the decline of Total Functional Capacity (TFC), which measures a patient's ability to live independently, manage finances, and perform daily chores. Researchers at University College London Hospitals described the data as the most convincing evidence of disease modification ever seen in the field.[3]

These clinical observations were supported by objective biomarker data indicating that the therapy reduces active brain damage. Neurofilament light chain (NfL) is a protein released into the cerebrospinal fluid when brain cells die; in Huntington's patients, NfL levels typically rise as the disease progresses. At 36 months, patients treated with high-dose AMT-130 saw an 8.2% reduction in NfL levels compared to their baseline, suggesting that the therapy was actively preventing neuronal death.[2]

Despite this evidence, the path to regulatory acceptance was severely disrupted in late 2025. Under the leadership of former FDA officials Vinay Prasad and Marty Makary, the agency abruptly rejected UniQure's plan to file for accelerated approval. The regulators argued that comparing the drug to an external natural history cohort was insufficient to prove efficacy, citing the potential for placebo effects.

To definitively prove the drug worked, the FDA initially demanded a randomized, placebo-controlled Phase 3 trial. Because AMT-130 is delivered surgically, this would have required a "sham surgery" control group—meaning half the trial participants would undergo anesthesia and have holes drilled into their skulls without receiving the actual gene therapy.

This demand sparked fierce ethical pushback. Patient advocacy groups, including Help4HD, argued that requiring sham brain surgeries for a fatal disease was an unacceptable and unethical hurdle. Advocates stressed that the natural history of Huntington's is well-documented and uniformly tragic, making an external control group a scientifically valid and morally necessary alternative.

The regulatory landscape shifted dramatically in May 2026, when Prasad and Makary departed the FDA. Under Acting Commissioner Kyle Diamantas, the agency has signaled a return to greater regulatory flexibility for rare diseases. The June 17 reversal on AMT-130 is viewed by industry analysts as a direct rebuke of the previous administration's inflexible scientific rigor.[1]

In its latest guidance, the FDA agreed that the three-year Phase 1/2 data is sufficient to serve as the primary basis for a Biologics License Application (BLA). Crucially, the agency also dropped the sham surgery requirement for the mandatory confirmatory trial, agreeing to let UniQure use patients on standard-of-care therapies as a concurrent control group.[1]

Financial markets reacted violently to the news, with UniQure's stock surging over 70% in premarket trading. The broader biotech sector also saw a lift, as investors interpreted the decision as a sign that the FDA is actively repairing its relationship with rare-disease drug developers.[1]

While the data is highly promising, transparent uncertainties remain regarding the drug's ultimate efficacy. The Phase 1/2 trial involved a very small sample size of fewer than 30 treated patients. Additionally, while a 75% slowing of progression is a massive clinical benefit, AMT-130 is not a cure; the disease still progresses, albeit at a much slower rate. The long-term durability of the gene silencing beyond three years is also unknown.[2][4]

UniQure now plans to submit its application for accelerated approval in the third quarter of 2026. If the FDA accepts and approves the filing, AMT-130 could be available to patients as early as 2027, fundamentally transforming the treatment landscape for one of neurology's most devastating diseases.[1][3]